MCH Banner  

The drug discovery landscape is rapidly changing and with it comes the need to generate leads with lower attrition rate. Property-based drug design approach is guiding researchers in designing candidates with the right balance of physicochemical properties - safety and absorption, distribution, metabolism, and excretion (ADME) profiles. 4th Annual Property-Based Drug Design in Medicinal Chemistry conference will bring together experts and leaders from industry and academia to share strategies and case studies for new and non-traditional molecules, how computational modeling and data management can be used effectively, and to discuss novel ways to measure or predict properties to make molecules more drug-like and overcome challenges in discovery, development, and the clinic.

Preliminary Agenda | Speaker Biographies 

Property-Based Structure Design Consideration for New & Non-Traditional Molecules 

Keynote Presentation: Exploring Macrocycles for Drug Discovery: Novel Lead Series for Challenging Protein-Protein Interactions

Nick TerrettNick Terrett, Ph.D., CSO, Ensemble Therapeutics Corp.

Designing Molecules with Better Deliverability and Targeting 

Optimizing Brain Exposure in CNS Drug Discovery

Ruben Alvarez SanchezRuben Alvarez Sanchez, Ph.D., Head of Pharmaceutical Profiling, Drug Disposition and Safety, F. Hoffmann-La Roche

Inhalation by Design: Approaches towards Designing Drug Candidates for Lung Diseases

Peter JonesPeter Jones, Ph.D., Senior Principal Scientist, Medicinal Chemistry - Inflammation and Remodelling, Pfizer, Inc.

Designing Properties to Overcome Challenges in Discovery, Development & Clinic 

Utilizing Physiologically-Based Pharmacokinetic Modeling to Inform Formulation and Clinical Development

Jan WahlstromJan Wahlstrom, Ph.D., Director, Pharmacokinetics & Drug Metabolism, Amgen, Inc.

A Systems Pharmacokinetics Approach to the Optimization of Drug Properties to Help Maximize Therapeutic Index: On the Quantitative Prediction of Unbound Tissue Distribution and its Implication for Drug Design

Avijit Ghosh, Ph.D., Director, Mechanism-Based Drug Disposition Pharmacodynamics and Metabolism, Janssen R&D

The Discovery and Development of an HIV-1 Attachment Inhibitor Clinical Candidate

Kap-Sun Yeung, Ph.D., Principal Scientist, Discovery Chemistry, Pharmaceutical R&D, Bristol-Myers Squibb Co.

Physicochemical Properties and Property-Based Drug Design in Heptatobilliary Transport

Manthena Varma, Ph.D., Senior Principal Scientist, Pharmacokinetics Dynamics & Metabolism, Pfizer, Inc.

Prediction and Evaluation of Drug Properties 

Physicochemical and Biomimetic Properties to Guide Lead Optimization

Klara ValkoKlara Valko, Ph.D., DSc, FRSC, Senior Scientific Investigator, UK Analytical Chemistry, RD Platform Technology & Science, GSK

Oral Druggable Space Beyond the Rule of 5: Insights from Drugs and Clinical Candidates

Jan KihlbergJan Kihlberg, Ph.D., Professor, Department of Chemistry, BMC, Uppsala University, Sweden

Computational Modeling and in silico Predication of Drug Properties

Terry Richard StouchTerry Richard Stouch, Ph.D., President, Science for Solutions, LLC

Phosphatidylcholine Affinity Chromatography and Link to Compound Promiscuity, Non-Specific Binding and Phospholipidosis Assessment

John ReillyJohn Reilly, Ph.D., Senior Research Investigator, Global Discovery Chemistry, Novartis

For questions about the meeting, please contact:
Nandini Kashyap
Conference Director
Cambridge Healthtech Institute
T: 781-972-5406

For sponsorship and exhibit information, contact:
Joseph Vacca
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5431

WPC Colocated Event 

Submit Speaker Proposal 




The exhibit hall has sold out the past four years, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2015, contact:

Joseph Vacca
Associate Director, Business Development